The first trial of generative AI therapy shows it might help with depression
-
A clinical trial of "Therabot," a generative AI therapy bot, showed comparable effectiveness to human therapy for individuals with depression, anxiety, or risk of eating disorders. However, the study's authors caution against widespread deployment of unregulated AI therapy tools, as most lack evidence-based training and oversight.
-
Key Themes:
- Efficacy of AI Therapy: The study suggests AI can effectively reduce symptoms of depression and anxiety and address body image concerns.
- Regulatory Concerns: The rapid proliferation of AI therapy companies operating without FDA oversight raises safety and ethical questions.
- Data Training Matters: The quality of the data used to train AI therapy models is crucial; general internet conversations are insufficient.
- Accessibility vs. Quality: Affordable, non-therapeutic chatbots may become more widely used for mental health support due to lack of approved and integrated digital therapies.
-
Notable Insights:
- Therabot achieved similar results to 16 hours of human therapy in about half the time.
- Many existing AI therapy bots may provide harmful advice, especially regarding topics like weight loss.
- Supervision of AI therapy bots may be necessary, which would limit their accessibility.
- The FDA's lack of enforcement in the AI therapy space is a significant concern, as most companies likely couldn't substantiate their claims if challenged.